Guardant Health Inc (GH) Stock Price, Quote & News

Company Profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling t...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 855 698 8887

Fax: 888 974 4258

Website: guardanthealth.com

Address:

3100 Hanover Street, Palo Alto, United States

DonCorleone77 Apr. 7 at 10:37 AM

$GH Citi adds 'upside 90-day catalyst watch' on Guardant Health Citi added an "upside 90-day catalyst watch" on shares of Guardant Health while keeping a Buy rating on the name with a $150 price target. Citi sees upside to Q1 estimates from higher selling prices and notes the stock's multiple has pulled back.

1 · Reply

LadyBABA Apr. 7 at 2:27 AM

$GH saw a Shield commercial, I think it was CBS

1 · Reply

Gator5326 Apr. 2 at 2:20 PM

$GH One word……buy 😎

0 · Reply

GoldenBum77 Apr. 1 at 2:04 PM

$GH Get in…..Now.

1 · Reply

CromieAds Apr. 1 at 1:46 PM

$CAI $EXAS $GH $GRAL

0 · Reply

CromieAds Mar. 31 at 11:44 PM

$CAI should run up nicely tomorrow. This is big news!… https://www.prnewswire.com/news-releases/caris-life-sciences-finalizes-achieve-1-study-results-reinforcing-the-superior-sensitivity-and-specificity-of-caris-detect-302730659.html $EXAS $GH $GRAL

1 · Reply

Gator5326 Mar. 31 at 11:35 PM

$GH

0 · Reply

GoldenBum77 Mar. 31 at 6:32 PM

$GH Something happened that hasn’t been announced to the public yet

1 · Reply

JasonCO Mar. 31 at 6:16 PM

$GH better

0 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

Guardant Health's InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

Mar 24, 2026, 9:15 AM EDT - 14 days ago

Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data

Mar 18, 2026, 8:05 AM EDT - 20 days ago

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

Mar 16, 2026, 8:05 AM EDT - 22 days ago

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

Mar 13, 2026, 8:05 AM EDT - 25 days ago

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

Mar 10, 2026, 8:05 AM EDT - 4 weeks ago

Guardant Health's Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics

Mar 4, 2026, 7:00 AM EST - 4 weeks ago

Guardant Health Launches Coast-to-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to Over 100 Communities Across America

Mar 3, 2026, 7:00 AM EST - 5 weeks ago

Actor and Cancer Advocate Patrick Dempsey Partners with Guardant Health to Raise Awareness about Colorectal Cancer Screening and Shield Blood Test, Sharing His Experience Getting Screened

Feb 27, 2026, 4:05 PM EST - 5 weeks ago

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 19, 2026, 4:05 PM EST - 6 weeks ago

Guardant Health Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

Feb 12, 2026, 2:35 PM EST - 7 weeks ago

Guardant Health Launches Community Colorectal Cancer Screening Grant Program in Recognition of CRC Awareness Month, Applications Now Open

Feb 3, 2026, 4:05 PM EST - 2 months ago

Guardant Health to Participate in Upcoming Investor Conferences

Feb 2, 2026, 8:05 AM EST - 2 months ago

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions

Jan 29, 2026, 4:05 PM EST - 2 months ago

Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Jan 22, 2026, 12:51 PM EST - 2 months ago

FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer

Jan 22, 2026, 8:05 AM EST - 2 months ago

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Jan 19, 2026, 8:05 AM EST - 2 months ago

Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Jan 11, 2026, 5:00 PM EST - 3 months ago

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Jan 8, 2026, 8:05 AM EST - 3 months ago

Guardant Health's Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families

Dec 29, 2025, 4:05 PM EST - 3 months ago

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 10:10 AM EST - 3 months ago

Global Healthy Living Foundation and Guardant Health Announce Partnership to Advance Awareness of Early Colorectal Cancer Detection and Improve Access to Screening

Dec 11, 2025, 8:05 AM EST - 4 months ago

Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.

Dec 9, 2025, 8:05 AM EST - 4 months ago

Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy

Dec 5, 2025, 8:05 AM EST - 4 months ago

Guardant Health to Present 14 Abstracts Demonstrating the Power of Multiomic Liquid Biopsy Tests in Predicting Outcomes and Tailoring Treatment for Early and Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium

Dec 2, 2025, 7:23 PM EST - 4 months ago

Senator Buys Coca-Cola, Hershey's Stock After Selling Magnificent Seven Stocks In 2025

HSY KO

Nov 20, 2025, 3:45 PM EST - 4 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO INSM LITE MP MU

Nov 18, 2025, 12:59 PM EST - 4 months ago

6 Healthcare Stocks With Strong Upward Momentum

ABVX CAH ELAN MEDP WGS

Nov 12, 2025, 8:05 AM EST - 5 months ago

Guardant Health Announces Launch of Single Namespace Group Uniting Leading Technology, Healthcare and Research Institutions to Set Global Standard for Exabyte-Scale Data Access

Nov 10, 2025, 8:05 AM EST - 5 months ago

Guardant Health Expands Tissue-Free Reveal Test to Include Late-Stage Therapy Response Monitoring

Nov 6, 2025, 8:05 AM EST - 5 months ago

New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

Nov 5, 2025, 4:05 PM EST - 5 months ago

Shield CRC Blood Test Demonstrates Adherence of 95% in New Study of 20,000 Patients

Nov 5, 2025, 2:15 AM EST - 5 months ago

Guardant Health Prices Upsized $350.0 Million Convertible Senior Notes Offering

Nov 5, 2025, 2:15 AM EST - 5 months ago

Guardant Health Announces Pricing of Upsized Public Offering of Common Stock

Nov 4, 2025, 4:39 PM EST - 5 months ago

Guardant Health Announces Proposed Public Offering of Common Stock

Nov 4, 2025, 4:38 PM EST - 5 months ago

Guardant Health Announces Proposed $300.0 Million Offering of Convertible Senior Notes Due 2033

Oct 29, 2025, 4:05 PM EDT - 5 months ago

Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Oct 27, 2025, 8:05 AM EDT - 5 months ago

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Oct 26, 2025, 3:01 PM EDT - 5 months ago

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Oct 15, 2025, 4:57 PM EDT - 6 months ago

Guardant Health and Collaborators to Present New Data Across the Cancer Care Continuum at ESMO 2025

Oct 9, 2025, 4:05 PM EDT - 6 months ago

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

Sep 29, 2025, 8:05 AM EDT - 6 months ago

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

Sep 24, 2025, 8:05 AM EDT - 6 months ago

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

DGX

Sep 15, 2025, 4:07 PM EDT - 7 months ago

Alex M. Azar II Joins Guardant Health Board of Directors

Sep 11, 2025, 8:05 AM EDT - 7 months ago

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

Sep 8, 2025, 8:05 AM EDT - 7 months ago

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

Sep 4, 2025, 8:06 AM EDT - 7 months ago

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

Aug 28, 2025, 4:05 PM EDT - 7 months ago

Guardant Health to Host Investor Day on September 24, 2025

Aug 26, 2025, 4:05 PM EDT - 7 months ago

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 4, 2025, 8:06 AM EDT - 8 months ago

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

Jul 31, 2025, 4:05 PM EDT - 8 months ago

Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

DonCorleone77 Apr. 7 at 10:37 AM

1 · Reply

LadyBABA Apr. 7 at 2:27 AM

$GH saw a Shield commercial, I think it was CBS

1 · Reply

Gator5326 Apr. 2 at 2:20 PM

$GH One word……buy 😎

0 · Reply

GoldenBum77 Apr. 1 at 2:04 PM

$GH Get in…..Now.

1 · Reply

CromieAds Apr. 1 at 1:46 PM

$CAI $EXAS $GH $GRAL

0 · Reply

CromieAds Mar. 31 at 11:44 PM

1 · Reply

Gator5326 Mar. 31 at 11:35 PM

$GH

0 · Reply

GoldenBum77 Mar. 31 at 6:32 PM

$GH Something happened that hasn’t been announced to the public yet

1 · Reply

JasonCO Mar. 31 at 6:16 PM

$GH better

0 · Reply

TrendEdgeLogan Mar. 31 at 5:21 PM

$GH $KYMR $IMNM $NAMS $SOPH OCS PVLA ZYM SRZN ^^ best of the best healthcare / biotech names right now

0 · Reply

IN0V8 Mar. 30 at 3:58 PM

$GH https://www.businesswire.com/news/home/20260330846159/en/Guardant-Healths-InfinityAI-Real-World-Evidence-Supports-Approval-of-ENHERTU-for-Previously-Treated-Patients-with-HER2-Positive-Metastatic-Solid-Tumors-in-Japan

0 · Reply

Gator5326 Mar. 30 at 12:38 PM

$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIAmim1Vav-2B8XDhBixN-2BEOZCIAq5dGjo4adBEYiS-2FEai-2FZHo-2FNy0ztwct3awZNv0Wfb1g8860duW2qqJtBrexkZMPeE3c9Vt6IkjSBG70XQ-2BfjHeNfyu8XZpWlBuNuthCjMx7o4pGj7ri-2B8ri76WcVqr0f-2F5Dz4n0i9xR9TvxpvxWvgSkAsngZL5ypUcaSfYOLLqLyjuYvv0fDOngU1crGI9A-3D-3D_HwZ_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMvvtD-2Bf5QIG5BpIjhF-2BgVDICRHH7rvVlzv5FEaAHkyWo-2FEsgMDXR25ucBbUVmNh20aP8-2FY-2B9Sg0Pye035I0KcmNYpmWy7R3PGi7AiE-2FpfsbhUDmTmTzbcxp-2FWg8Z-2FTallQ8-2FANPpenc7sOQCjmnpZ4a0384V7PdM3EDM0IdTqcAbe-2BBqevSXUTA9f7LOutwVUABaip7lbPxjrI3Zc2-2FiHfoSgVYBoIYZfOtcqFcDIHuVD6VRqYMK1Ua6GCAez33lobTAWCzk0g6oK3LdDwJDv2SdK93yefdRqHDRp74Cv0G7pRe9YrAMHWT9maHCAJE6azatcimRxvZoZckg8bqCcL5Ck4-2F3kvXbaY63H2CfrxXXHKpsJnaStkrYISLZq6HIZA-3D-3D

0 · Reply

JasonCO Mar. 25 at 5:45 PM

$GH nice move going

0 · Reply

OffHisGame88 Mar. 25 at 4:36 PM

$GH really cheap considering the acceleration of growth

0 · Reply

LadyBABA Mar. 25 at 6:49 AM

$GH still in channel

1 · Reply

Gator5326 Mar. 18 at 1:41 PM

$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIA243hJjC5CJS5rkv-2BozOxXBePAmNpgvmD2zSIApV6gJ-2FPLfFEX4Jc6UIOQBfrESlGtEwydSrbIiNt88leefix3K8D4UASyvPWJP5vjPye672AlZt9btC4vUDJoJyoN6BW67a9vyLxJ7a6k8Ru0pob6nxKoAb27-2BU3uxZA0-2BHiMTTTNrBci2y0msV8Gvp4ZjA43GlK4cz4404WcE-2Fiqo5vQT29Ibl4IX4BDZDlB-2FyliPw-3DuU7r_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMqfk4NRY1V1Yir-2FJgxEvDALy2fSjAZwWCPrIQ8X8PbJcKyuDR5U5EMC8ks3MmhdRfOafhQ-2B4cplgmpKZV0Cc8X2Yr488iDprCnDbljpWtoaggKV6b1Ke3Tar-2BwiUl16hirqZ2W8zttFq-2FMdgK4aTI-2FWgyoNmmZ6gzg9JhqvJQRgzUh6ZV7Rc9EVKWh9u8-2FApCaaza-2Fpdwm0QlGlB6gAVxzptm9zUxzhlM3r1NYi-2Fabc40E6Timl0hqHDGmfqzqTq-2BFZEO3wFvITK7u6UI8VJ-2BZInUs82fpl-2Bc7mJIL-2FfH9HB3aTI8GGFXXAfGyt0HWDiRE67GbO9-2BmS0MCLGv4f4tRPvSum-2B9ROZ-2FnXx8GnLDeOQM0UyNMLSGvdWLB9cas-2FiWg-3D-3D

0 · Reply

Cutlass Mar. 16 at 1:19 PM

$GH Been dropping for 8 weeks now - Will wait, on watch 👀

1 · Reply

Gator5326 Mar. 16 at 1:03 PM

$GH How awesome is $GH? “By being the first insurer in Asia to offer the Shield MCD test, we’re empowering our customers with a credible and valued service that encourages proactive health management,” said Steve Finch, President and CEO of Manulife Asia. “This exclusive partnership demonstrates our commitment to offering innovative and differentiated solutions to improve the health outcomes of our customers.”

0 · Reply

Gator5326 Mar. 16 at 12:14 PM

$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyf7-2BfqgDTPA1pwQgPEK0LIA8n6vjeFh7ltQM-2FMG941fInP13SAcMpRo6VDsnUg7wblttRy5hVbEExlnHG1xLYP4F7XhCPe6vj6Eqx3RMAN8lvT6sMgbaDJim-2FJ3hpO8MVblQwC-2F75wUn30yHteYUQZgaJ4DtTX6zbkXHC3G7fHjipE0KJW26gDHiuKCoNregYQ-3DeWLb_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRgIG36Opi-2BfPD0wkS0BpMi-2FR4SgqcBs7yQ0n-2F4ewtV-2FoySDDLHo55fynoKdW-2FF8L2AP41DZU8YxMc5jJngulijGCo4ufujXTXqs5zQKf4ABhdVsaTKWqDj2U5u8B22GvnAbXECVsb1d83ip4se7iRxEJtoiX2-2BboDSJBtwMZFkNQltlxB-2BWzVnSvuaVshJIo5kjCu-2B56EiFHir6kWZnVOWGKCzgn-2BqVgLNFvO4D5sNUdlsSvfeQMWNEj2m2HqKE7qwgL9cbAux-2FmHOnDZ8f5xMnx2nD5XsA7L0ds8lR997EJ4rWV-2B8tmz6fIu6ByIgTSJYjR12gWVthfvjNbg2Mrog-3D-3D

0 · Reply

Gator5326 Mar. 13 at 8:41 PM

$GH https://m.facebook.com/story.php?story_fbid=pfbid02F7c781W1Cpy6zKY8ko9Lm7DPSGHhmSJ4Lb6wi7bD9f74GtC4dNbPCbDL4QARferhl&id=100044244079017

0 · Reply

Gator5326 Mar. 13 at 12:12 PM

$GH https://u18966101.ct.sendgrid.net/ls/click?upn=u001.4ITdg8fiPHHXRRODKhpNknNKs0V2h8ItR6Q2oQCQKcTyRrxC8ZerlixSyXRNZh4ketL7E2RWkAerRsZCr7TPZyHSCsppSPtyeGddfxO4qyc0ykOikWEhSXYW21xyo5BdQN35uOTs4e7SRVbKJrb8qqHmK9yVCU4R4OX1GhDmqkgXZjS9ywBPtvYt16xmVBD5MGzzYjyqIpDxYb0sUmINArAMnFB0IodpoXW5FulLy4r6l1iBKWaS02pM-2BE25dJYkXwvcZQYJH6yVqoCCen0dqjbJdX2H-2B3X8AXCiWBB1xNeZDRUmNAwpQf1a4VGFycve-2Few3HjlyzHNvUu0WzNQXRjSnNoVaE7n1KD-2FqdWwUDkY-3DI3Hf_n7gaS9t6bMxECCQWPRdwdqPZyOAjF4RSivuNxLLPR-2FSmysoqQW1ClVyewMaUHyr5PXnLg-2BfGbSor9w1GLElWTiEw3tZro1MLP1IzWdS5qPpbfYGAtnJcrhAqCrHeCZaHRaWxdbhNYu4J6vtCfFut8RKM6aMY3xxO09R1HfVxhAsH6qUmo2jAgLi2Ejzky02-2B1-2Bfdy82ibTWoWWv7E-2Fp9obLiSHe8Txnezpfe7ekSBSyKlVN-2BkbNa2njSnruPZEKDbhxqK-2Bw-2FRaEt9ycuFNtEI9diHACLr9vnOHwaUwIv16MScV38nmCgrjN4mcrKgdjhRDXpRjIDI1Z159HuckffsGXfjMhesMS2aysuTBl-2BSN3R5qmzS9kZhmY2hFnnc9Zs-2BA0wyTdQ24X9qagOAtguWkVkFxs2OdL-2B4tIU67i5oazXFcVyySaLHifdCUZ4JFwbaqk-2BHyFmVc4IsU3urJV0ToEotL8wON3JUzs5a3EtI5x-2FBVdxij91kMYAbt3j9ppzhAVdoumd8Hh8F-2B16I0JvgQ-3D-3D

1 · Reply

123rs123 Mar. 13 at 8:03 AM

$GH market gifted us with an insane discount, instabuy at these levels

1 · Reply

Market Cap	12.31B
Revenue (ttm)	982.02M
Net Income (ttm)	-416.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-42.39%
Debt to Equity Ratio	-15.14

Volume	1,066,500
Avg Vol	1,927,154
Day's Range	N/A - N/A
Shares Out	131.17M
Stochastic %K	52%
Beta	1.64
Analysts	Strong Sell
Price Target	$134.50